

Appl. No. 09/585,817
Amdt. dated May 15, 2003
Reply to Office Action of December 4, 2003

AMENDMENTS TO THE SPECIFICATION:

Please amend the paragraph beginning on page 25, line 23 as follows:

By way of example, as described above, the therapeutic agent used in treating Alzheimer's disease or other amyloid diseases characterized by A β fibril deposition can be any of the naturally occurring forms of A β peptide, and particularly the human forms (i.e., A β 39, A β 40, A β 41, A β 42 or A β 43). The sequences of these peptides and their relationship to the APP precursor are known in the art and are well known in the art (e.g., Hardy et al., TINS 20, 155-158 (1997)). For example, A β 42 has the sequence:

H2N-Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val-Ile-Ala-OH. (SEQ ID NO: 4 34)

Please enter the enclosed paper copy of the Sequence Listing, pages 1-11, at the end of the application.